<DOC>
	<DOC>NCT02245672</DOC>
	<brief_summary>The purpose of this study is to determine whether MGR001 is equivalent to Advair Diskus when administered by inhalation in adult asthma patients</brief_summary>
	<brief_title>MGR001 / Advair Diskus Local Equivalence Study in Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Key inclusion criteria include: Male or female subjects aged ≥18 years. Females may be of either childbearing or nonchildbearing potential Physician diagnosed history of asthma for at least 12 weeks prior to screening prebronchodilator FEV1 6085% at screening and other specified visits Postbronchodilator reversibility &gt;/=12% Nonsmokers and prior smokers with no history of smoking within the past 12 months prior to screening and a total smoking history of ≤10 packyears Subjects able to discontinue asthma medications for the duration of the study and be maintained using albuterol as required Body mass index between 1840 kg/m2 inclusive Key exclusion criteria include: Presence or recent history of any other active, severe, progressive, and/or uncontrolled clinical disease, eg, poorly controlled Type 1 or 2 diabetes, seizure disorder or epilepsy, cerebrovascular accident, significant cardiac conduction abnormalities Respiratory conditions other than asthma and allergic rhinitis, including but not limited to: severe nasal polyposis or chronic rhinosinusitis, chronic obstructive pulmonary disease, bronchiectasis, ChurgStrauss Disease, lung resection, pulmonary fibrosis (primary or secondary), pulmonary hypertension, cystic fibrosis, sarcoidosis History of lifethreatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnia; respiratory arrest or hypoxic seizures, asthma related syncopal episode(s) In patient hospitalization (not including ER visits) for an asthma exacerbation within the past year or during the run in period An asthma exacerbation requiring change in asthma therapy or oral/IV corticosteroids in the 3 months prior to screening History of seasonally unstable asthma where the season will coincide with the subject's participation in the study Use of prescription or nonprescription drugs, including beta blockers, tricyclic antidepressants, oral decongestants, benzodiazepines, digitalis, phenothiazines, monoamine oxidase inhibitors, etc Suspected hypersensitivity to the study drugs (including lactose) or severe milk protein allergy Clinically significant abnormalities in the screening ECG Evidence of alcohol or drug abuse or dependency within 6 months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>fluticasone</keyword>
	<keyword>salmeterol</keyword>
	<keyword>CRC749</keyword>
	<keyword>Diskus</keyword>
	<keyword>Advair</keyword>
	<keyword>FEV1</keyword>
	<keyword>MGR001</keyword>
</DOC>